Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7176-7186

  Zhang, Xinna ^a   Wan, Guohui ^a   Mlotshwa, Sizolwenkosi ^a   Vance, Vicki ^a   Berger, Franklin G ^a   Chen, Hexin ^a   Lu, Xiongbin ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; DOXORUBICIN; MICRORNA; MIR 16; PROTEIN P53; UNCLASSIFIED DRUG; WILD TYPE P53 INDUCED PHOSPHATASE 1; 3' UNTRANSLATED REGION; MIRN16 MICRORNA, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE 2C;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BONE TUMOR; BREAST TUMOR; CELL GROWTH; ENZYME INDUCTION; ENZYMOLOGY; GENE AMPLIFICATION; GENETIC TRANSFECTION; GENETICS; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA DAMAGE; DOWN-REGULATION; ENZYME INDUCTION; GENE AMPLIFICATION; HUMANS; MICE; MICE, TRANSGENIC; MICRORNAS; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; PHOSPHOPROTEIN PHOSPHATASES; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77956896318     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0697     Document Type: Article

References (42)

1. Lu X, Nguyen TA, Donehower LA. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle 2005;4:1060-4.
2. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008;27:123-35.
3. Shreeram S, Demidov ON, Hee WK, et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 2006; 23:757-64.
4. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005;19: 1162-74.
5. Fujimoto H, Onishi N, Kato N, et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ 2006;13:1170-80.
6. Takekawa M, Adachi M, Nakahata A, et al. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19:6517-26.
7. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007;12:342-54.
8. Zhang X, Lin L, Guo H, et al. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res 2009;69:7960-8.
9. Choi J, Nannenga B, Demidov ON, et al. Mice deficient for the wildtype p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol 2002;22:1094-105.
10. Li J, Yang Y, Peng Y, et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002;31:133-4.
11. Saito-Ohara F, Imoto I, Inoue J, et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003;63:1876-83.
12. Hirasawa A, Saito-Ohara F, Inoue J, et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003;9:1995-2004.
13. Loukopoulos P, Shibata T, Katoh H, et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 2007;98:392-400.
14. Ehrbrecht A, Muller U, Wolter M, et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 2006;208:554-63.
15. Castellino RC, De BM, Lu X, et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neuroonco 2008;86: 245-56.
16. Fuku T, Semba S, Yutori H, Yokozaki H. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int 2007;57:566-71.
17. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
18. Pothof J, Verkaik NS, van IW, et al. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 2009;28:2090-9.
19. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009;460: 529-33.
20. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A 2010;107:1506-11.
21. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-7.
22. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6: R605-15.
23. Fiscella M, Zhang H, Fan S, et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 1997;94: 6048-53.
24. Rossi M, Demidov ON, Anderson CW, Appella E, Mazur SJ. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic Acids Res 2008;36:7168-80.
25. Bulavin DV, Demidov ON, Saito S, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002;31:210-5.
26. Bulavin DV, Phillips C, Nannenga B, et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004;36:343-50.
27. Natrajan R, Weigelt B, Mackay A, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010;121:575-89.
28. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009;15:2711-22.
29. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjarvi T, Kallioniemi A. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 2006;95:257-63.
30. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102: 13944-9.
31. Demidov ON, Kek C, Shreeram S, et al. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007;26:2502-6.
32. Kim ND, Oberley TD, Yasukawa-Barnes J, Clifton KH. Stem cell characteristics of transplanted rat mammary clonogens. Exp Cell Res 2000;260:146-59.
33. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
34. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70.
35. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003;36 Suppl 1:59-72.
36. Rayter S, Elliott R, Travers J, et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 2008; 27:1036-44.
37. Macurek L, Lindqvist A, Voets O, Kool J, Vos HR, Medema RH. Wip1 phosphatase is associated with chromatin and dephosphorylates ãH2AX to promote checkpoint inhibition. Oncogene 2010; 29:2281-91.
38. Moon SH, Lin L, Zhang X, et al. Wildtype p53-induced phosphatase 1 dephosphorylates histone variant ã-H2AX and suppresses DNA double strand break repair. J Biol Chem 2010;285:12935-47.
39. Lu X,BocangelD,NannengaB, Yamaguchi H,Appella E,Donehower LA. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell 2004;15:621-34.
40. Song JY, Han HS, Sabapathy K, Lee BM, Yu E, Choi J. Expression of a homeostatic regulator, Wip1 (wild-type p53-induced phosphatase), is temporally induced by c-Jun and p53 in response to UV irradiation. J Biol Chem 2010;285:9067-76.
41. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008;68:4674-82.
42. Godar S, Ince TA, Bell GW, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008;134:62-73.